Literature DB >> 6268347

Hormonal responses to long-term converting enzyme inhibition in hypertensive patients.

T Ogihara, A Maruyama, T Hata, H Mikami, M Nakamaru, T Naka, H Ohde, Y Kumahara.   

Abstract

Captopril was given alone and in combination with diuretics to 49 patients with hypertension for 1 to 12 mol Within 2 mo blood pressure reduction correlated with pretreatment plasma renin activity and response to the infusion of angiotensin II antagonist, but these effects were not present at 4 mo. Plasma and urinary aldosterone were suppressed but serum converting enzyme activity, plasma bradykinin, kallikren, and prostaglandins (E and F) were in the normal range effect of captopril. Despite sustained reduction of blood pressure, plasma catecholamines were not elevated and urinary catecholamines were suppressed in patients on captopril alone. It is concluded that another mechanism, such as enhancement of renal or local kinin-prostaglandin system, as well as suppression of the renin-angiotensin-aldosterone system may be involved in the long-term efficacy of captopril. Sympathetic activity may also be depressed and contribute to the hypotensive effect.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6268347     DOI: 10.1038/clpt.1981.168

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  2 in total

1.  The effect of tenidap on the anti-hypertensive efficacy of ACE inhibitors in patients treated for mild to moderate hypertension.

Authors:  W G Rapeport; V C Grimwood; J Hosie; P M Sloan; K Korlipara; B D Silvert; I James; G L Mechie; J L Anderton
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

Review 2.  Involvement of the kallikrein-kinin system in the antihypertensive effect of the angiotensin converting enzyme inhibitors.

Authors:  B Waeber; L Juillerat-Jeanneret; J F Aubert; M Schapira; J Nussberger; H R Brunner
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.